Goldman Sachs’s ALX Oncology ALXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $120K | Sell |
289,693
-83,521
| -22% | -$34.7K | ﹤0.01% | 4846 |
|
|
2025
Q1 | $233K | Sell |
373,214
-195,795
| -34% | -$122K | ﹤0.01% | 4616 |
|
|
2024
Q4 | $950K | Buy |
569,009
+312,130
| +122% | +$521K | ﹤0.01% | 3948 |
|
|
2024
Q3 | $468K | Buy |
256,879
+41,627
| +19% | +$75.8K | ﹤0.01% | 4145 |
|
|
2024
Q2 | $1.3M | Buy |
215,252
+58,250
| +37% | +$351K | ﹤0.01% | 3466 |
|
|
2024
Q1 | $1.75M | Buy |
157,002
+66,259
| +73% | +$739K | ﹤0.01% | 3279 |
|
|
2023
Q4 | $1.35M | Sell |
90,743
-40,384
| -31% | -$601K | ﹤0.01% | 3457 |
|
|
2023
Q3 | $629K | Sell |
131,127
-48,640
| -27% | -$233K | ﹤0.01% | 3782 |
|
|
2023
Q2 | $1.35M | Sell |
179,767
-880
| -0.5% | -$6.61K | ﹤0.01% | 3434 |
|
|
2023
Q1 | $817K | Buy |
180,647
+5,186
| +3% | +$23.4K | ﹤0.01% | 3800 |
|
|
2022
Q4 | $1.98M | Buy |
175,461
+14,715
| +9% | +$166K | ﹤0.01% | 3287 |
|
|
2022
Q3 | $1.54M | Sell |
160,746
-86,997
| -35% | -$833K | ﹤0.01% | 3544 |
|
|
2022
Q2 | $2M | Buy |
247,743
+33,257
| +16% | +$269K | ﹤0.01% | 3450 |
|
|
2022
Q1 | $3.63M | Buy |
214,486
+75,348
| +54% | +$1.27M | ﹤0.01% | 3052 |
|
|
2021
Q4 | $2.99M | Sell |
139,138
-23,858
| -15% | -$513K | ﹤0.01% | 3192 |
|
|
2021
Q3 | $12M | Buy |
162,996
+26,663
| +20% | +$1.97M | ﹤0.01% | 2118 |
|
|
2021
Q2 | $7.46M | Sell |
136,333
-117,052
| -46% | -$6.4M | ﹤0.01% | 2485 |
|
|
2021
Q1 | $18.7M | Buy |
253,385
+121,757
| +93% | +$8.98M | ﹤0.01% | 1731 |
|
|
2020
Q4 | $11.3M | Buy |
131,628
+124,247
| +1,683% | +$10.7M | ﹤0.01% | 1972 |
|
|
2020
Q3 | $279K | Buy |
+7,381
| New | +$279K | ﹤0.01% | 3933 |
|